PDS Biotechnology Corp To Host Key Opinion Leader Call Transcript
Hello, and welcome to the PDS Biotechnology Interleukin-12 KOL Roundtable. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Dr. Lauren V. Wood. Please go ahead, Doctor.
Good morning, and welcome to PDS Biotech's Interleukin-12 or IL-12 KOL Roundtable. With me today are Dr. James Gulley and Dr. Jeffrey Schlom from the National Cancer Institute. I will provide formal introductions in a moment. But before we begin, I would like to caution listeners that comments made during this webcast may include forward-looking statements within the meaning of federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements involve material risks and uncertainties, and the company's actual results may differ materially. For a discussion of these risk factors, please refer to PDS Biotech's SEC filings. Investors, potential investors and other
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |